Literature DB >> 21366874

The rno-miR-34 family is upregulated and targets ACSL1 in dimethylnitrosamine-induced hepatic fibrosis in rats.

Wei-Qing Li1, Chao Chen, Mi-Die Xu, Jia Guo, Yi-Ming Li, Qing-Mei Xia, Hui-Min Liu, Jin He, Hong-Yu Yu, Liang Zhu.   

Abstract

The mechanisms whereby hepatic fibrosis develops in chronic liver diseases remain incompletely defined. Here, we sought to examine whether microRNA (miRNA) became dysregulated in dimethylnitrosamine-induced hepatic fibrosis in rats. Our microarray analysis revealed that the miR-34 family was upregulated along with other miRNAs in liver fibrotic tissues. Six miRNAs, such as rno-miR-878, were downregulated. The findings were confirmed by RT-PCR assays. Gene ontology analysis further showed that many of these dysregulated miRNAs were involved in lipid/fatty acid metabolism. The acyl-CoA synthetase long-chain family member 1 (ACSL1) gene contained specific binding sites for miR-34a/miR-34c. Additional enhanced green fluorescence protein reporter activity assays indicated that the miR-34 family targeted ACSL1. Our RT-PCR and immunoblotting assays further demonstrated that both the mRNA and protein levels of ACSL1 were markedly reduced in fibrotic liver tissues. Our findings suggest that miRNA becomes dysregulated during hepatic fibrosis, and that the miR-34 family may be involved in the process by targeting ACSL1. Journal compilation
© 2011 FEBS. No claim to original Chinese government works.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21366874     DOI: 10.1111/j.1742-4658.2011.08075.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  50 in total

1.  MicroRNAs in hepatic pathophysiology in diabetes.

Authors:  Kirandeep Kaur; Himanshi Bhatia; Malabika Datta
Journal:  World J Diabetes       Date:  2011-10-15

Review 2.  MicroRNA: a connecting road between apoptosis and cholesterol metabolism.

Authors:  Yogita K Adlakha; Neeru Saini
Journal:  Tumour Biol       Date:  2016-04-22

3.  Maternal chromium restriction modulates miRNA profiles related to lipid metabolism disorder in mice offspring.

Authors:  Qian Zhang; Xinhua Xiao; Jia Zheng; Ming Li; Miao Yu; Fan Ping; Zhixin Wang; Cuijuan Qi; Tong Wang; Xiaojing Wang
Journal:  Exp Biol Med (Maywood)       Date:  2017-07-01

4.  Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis.

Authors:  Markus Kaller; Sven-Thorsten Liffers; Silke Oeljeklaus; Katja Kuhlmann; Simone Röh; Reinhard Hoffmann; Bettina Warscheid; Heiko Hermeking
Journal:  Mol Cell Proteomics       Date:  2011-05-12       Impact factor: 5.911

Review 5.  Molecular determinants of mesenchymal cell activation in fibroproliferative diseases.

Authors:  Loka R Penke; Marc Peters-Golden
Journal:  Cell Mol Life Sci       Date:  2019-09-28       Impact factor: 9.261

6.  Selection of reference genes for miRNA quantitative PCR and its application in miR-34a/Sirtuin-1 mediated energy metabolism in Megalobrama amblycephala.

Authors:  Jie Liu; Erteng Jia; Huajuan Shi; Xiangfei Li; Guangzhen Jiang; Cheng Chi; Wenbin Liu; Dingdong Zhang
Journal:  Fish Physiol Biochem       Date:  2019-05-24       Impact factor: 2.794

Review 7.  MicroRNAs in metabolism and metabolic disorders.

Authors:  Veerle Rottiers; Anders M Näär
Journal:  Nat Rev Mol Cell Biol       Date:  2012-03-22       Impact factor: 94.444

Review 8.  Delivery and targeting of miRNAs for treating liver fibrosis.

Authors:  Virender Kumar; Ram I Mahato
Journal:  Pharm Res       Date:  2014-09-04       Impact factor: 4.200

9.  A micro-RNA expression signature for human NAFLD progression.

Authors:  Yan Guo; Yanhua Xiong; Quanghu Sheng; Shilin Zhao; Julia Wattacheril; Charles Robb Flynn
Journal:  J Gastroenterol       Date:  2016-02-13       Impact factor: 7.527

Review 10.  MicroRNAs in the p53 network: micromanagement of tumour suppression.

Authors:  Heiko Hermeking
Journal:  Nat Rev Cancer       Date:  2012-08-17       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.